Sepsis, July 2026 edition

In 223 ICU patients with suspected sepsis, plasma and whole-blood multiplex ddPCR detected clinically relevant pathogens more frequently than blood culture alone in culture-negative cases. Whole-blood ddPCR detected Candida more often than plasma ddPCR, suggesting a specimen-specific role in suspected fungal sepsis.

Impact: This prospective multicenter study directly addresses the delay and limited sensitivity of conventional pathogen identification in sepsis and provides clinically relevant evidence for specimen-specific molecular testing.

Clinical Implications: Paired plasma and whole-blood ddPCR could be used as an adjunct to blood culture when rapid pathogen identification is required, particularly when invasive candidiasis is suspected. It should not yet replace culture or clinical interpretation.

In a rat model of traumatic sepsis, proteomic analysis and loss-of-function experiments identified March5 as a suppressor of myocardial ferroptosis. Semaglutide increased March5 expression, reduced ACSL4-associated ferroptotic injury, and lost its cardioprotective effect when March5 was silenced.

Impact: The study links an unbiased proteomic discovery to causal genetic validation and identifies a potentially repurposable metabolic drug as a targeted therapy for septic myocardial dysfunction.

Clinical Implications: Semaglutide and the March5–ACSL4 pathway warrant further investigation for septic myocardial dysfunction, but the evidence remains preclinical and requires human cardiomyocyte studies, dose and timing studies, large-animal validation, and clinical trials.

This mechanistic study identified hepatocyte retinoid X receptor alpha as a regulator of hepatic metabolic stability and antibacterial defense during polymicrobial sepsis. Sepsis reduced RXRα expression, while hepatocyte-specific RXRα loss depleted Kupffer cells, promoted bacterial dissemination, and increased mortality. Prophylactic but not therapeutic bexarotene improved survival in mice, emphasizing treatment timing.

Impact: The study links hepatocyte transcriptional regulation to maintenance of the hepatic immune niche and systemic bacterial clearance, identifying a time-sensitive host-resilience mechanism.

Clinical Implications: RXRα activation could become an early biomarker-guided strategy to preserve hepatic immune-metabolic function, but human validation, optimal timing, dosing, and safety assessment are required.

This randomized phase 1/2 trial evaluated an investigational hexavalent group B Streptococcus conjugate vaccine in non-pregnant and pregnant participants and their infants. The program targets prevention of neonatal invasive GBS disease, including bloodstream infection, sepsis, meningitis, and death, through maternal immunization and transplacental antibody transfer.

Impact: A successful maternal GBS vaccine could prevent neonatal sepsis before it occurs and represents a major upstream prevention strategy for a population with substantial morbidity and mortality.

Clinical Implications: The findings support continued development toward phase 3 efficacy trials. Future evaluation must address pregnancy safety, gestational timing, antibody durability, serotype coverage, cost-effectiveness, and regional epidemiology.

The DNA aptamer ZH-1a binds the proinflammatory HMGB1 B-box with nanomolar affinity, suppresses cytokine signaling and NF-kB activation, and reduces late-phase inflammation and organ injury in multiple models. In polymicrobial sepsis, ZH-1a improved survival, supporting domain-specific neutralization of a late inflammatory mediator.

Impact: It provides a highly specific biologic approach to late-phase sepsis inflammation and offers a potential alternative to nonspecific global immunosuppression.

Clinical Implications: HMGB1-neutralizing aptamers may eventually be useful in patients with persistent inflammation or organ injury after initial resuscitation. Translation requires stability optimization, delivery studies, pharmacokinetic and safety assessment, and biomarker-guided trials.